Search research articles
Contact Us
Filters
Showing results (191-200 of 241) with videos related to
Page
of 25
Sort By:
The Lancet. Oncology
|
March 22, 2015
Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study
Martin Fassnacht, Alfredo Berruti, Eric Baudin, et al.
Journal of Personalized Medicine
|
April 30, 2021
What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question
Vittoria Basile, Soraya Puglisi, Barbara Altieri, et al.
Nature Medicine
|
April 26, 2022
Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial
Olivier Mir, Marie Ferrua, Aude Fourcade, et al.
International Journal of Cancer
|
April 23, 2014
SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma
Julien Hadoux, Judith Favier, Jean-Yves Scoazec, et al.
European Urology
|
November 26, 2013
Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer
Alfredo Berruti, Martin Fassnacht, Harm Haak, et al.
European Journal of Human Genetics : EJHG
|
August 2, 2007
Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD
Barbara Pasini, Sarah R McWhinney, Thalia Bei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 30, 2005
Genetic testing in pheochromocytoma or functional paraganglioma
Laurence Amar, Jérôme Bertherat, Eric Baudin, et al.
Annals of Surgery
|
March 7, 2017
Long-term Follow-up of MEN1 Patients Who Do Not Have Initial Surgery for Small ≤2 cm Nonfunctioning Pancreatic Neuroendocrine Tumors, an AFCE and GTE Study: Association Francophone de Chirurgie Endocrinienne & Groupe d'Etude des Tumeurs Endocrines
Frederic Triponez, Samira M Sadowski, François Pattou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 4, 2019
Tumor Growth Rate as a Validated Early Radiological Biomarker Able to Reflect Treatment-Induced Changes in Neuroendocrine Tumors: The GREPONET-2 Study
Angela Lamarca, Maxime Ronot, Salma Moalla, et al.
Cancers
|
March 19, 2020
Cancer-testis Antigen FATE1 Expression in Adrenocortical Tumors Is Associated with A Pervasive Autoimmune Response and Is A Marker of Malignancy in Adult, but Not Children, ACC
Mabrouka Doghman-Bouguerra, Pascal Finetti, Nelly Durand, et al.
Page
of 25
Search research articles
Search
Showing results (191-200 of 241) with videos related to
Sort By:
Page
of 25
The Lancet. Oncology
|
March 22, 2015
Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study
Martin Fassnacht, Alfredo Berruti, Eric Baudin, et al.
Journal of Personalized Medicine
|
April 30, 2021
What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question
Vittoria Basile, Soraya Puglisi, Barbara Altieri, et al.
Nature Medicine
|
April 26, 2022
Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial
Olivier Mir, Marie Ferrua, Aude Fourcade, et al.
International Journal of Cancer
|
April 23, 2014
SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma
Julien Hadoux, Judith Favier, Jean-Yves Scoazec, et al.
European Urology
|
November 26, 2013
Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer
Alfredo Berruti, Martin Fassnacht, Harm Haak, et al.
European Journal of Human Genetics : EJHG
|
August 2, 2007
Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD
Barbara Pasini, Sarah R McWhinney, Thalia Bei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 30, 2005
Genetic testing in pheochromocytoma or functional paraganglioma
Laurence Amar, Jérôme Bertherat, Eric Baudin, et al.
Annals of Surgery
|
March 7, 2017
Long-term Follow-up of MEN1 Patients Who Do Not Have Initial Surgery for Small ≤2 cm Nonfunctioning Pancreatic Neuroendocrine Tumors, an AFCE and GTE Study: Association Francophone de Chirurgie Endocrinienne & Groupe d'Etude des Tumeurs Endocrines
Frederic Triponez, Samira M Sadowski, François Pattou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 4, 2019
Tumor Growth Rate as a Validated Early Radiological Biomarker Able to Reflect Treatment-Induced Changes in Neuroendocrine Tumors: The GREPONET-2 Study
Angela Lamarca, Maxime Ronot, Salma Moalla, et al.
Cancers
|
March 19, 2020
Cancer-testis Antigen FATE1 Expression in Adrenocortical Tumors Is Associated with A Pervasive Autoimmune Response and Is A Marker of Malignancy in Adult, but Not Children, ACC
Mabrouka Doghman-Bouguerra, Pascal Finetti, Nelly Durand, et al.
Page
of 25